

47 Views | 11 CrossRef citations to date | 1 Altmetric

Editorial


Medicines for pediatric oncology: can we overcome the failure to deliver?

Agnes Saint-Raymond & Ralf Herold

Pages 493-495 | Published online: 10 Jan 2014

Cite this article <https://doi.org/10.1586/ecp.12.51>

Sample our
Bioscience
Journals



>> [Sign in here](#) to start your access
to the latest two volumes for 14 days

Full Article

Figures & data

References

Citations

Metrics

Reprints & Permissions

Read this article

Share

We Care About Your Privacy

We and our 880 partners store and access personal data, like browsing data or unique identifiers, on your device. Selecting I Accept enables tracking technologies to support the purposes shown under we and our partners process data to provide. Selecting Reject All or withdrawing your consent will disable them. If trackers are disabled, some content and ads you see may not be as relevant to you. You can resurface this menu to change your choices or withdraw consent at any time by clicking the Show Purposes link on the bottom of the webpage. Your choices will have effect within our Website. For more details, refer to our Privacy Policy. [Here](#)

We and our partners process data to provide:

Use precise geolocation data. Actively scan device

I Accept

Reject All

Show Purpose



For reprint orders, please contact reprints@expert-reviews.com

Medicines for pediatric oncology: can we overcome the failure to deliver?

Expert Rev. Clin. Pharmacol. 5(5), 493–495 (2012)



Agnes Saint-Raymond

Author for correspondence:
European Medicines Agency,
7 Westferry Circus, Canary
Wharf, London E14 4HB, UK
Tel.: +44 207 523 7017
Fax: +44 207 523 7040
agnes.saint-raymond@ema.europa.eu



Ralf Herold

European Medicines Agency,
7 Westferry Circus, Canary
Wharf, London E14 4HB, UK

“The way forward regarding pediatric oncology is under discussion by the Committee and may include revoking the condition waivers, giving back to the Committee the possibility to analyze the mechanism of action and target of the new medicines in order to eventually obtain the necessary data in children within a reasonable timeframe.”

To date, children do not have access to the medicines necessary to treat pediatric cancers. Pediatric tumors have different names and specificities from adult tumors that go far beyond the naming issue. In most other therapeutic areas, with the main exception in pediatric rheumatology, the diseases affecting children are close to those affecting adults with respect to type of diseases and pathophysiology. Owing to specific gene mutation and expression profiles and fast tumor growth, cancers affecting children are different. An aggravating factor for the lack of authorized medicines is the rarity of the diseases, representing a small market overall, although they are frequent among serious pediatric diseases. Cancer represents the second main cause of death in children and treatments place a heavy burden on the child and his or her family. The uncertainties on long-term prognosis owing to potential late relapses, as well as complications of chemotherapy and radiotherapy add to this burden. However, pediatric oncology is also the area where treatments have achieved outstanding results through rigorous protocols (using medicines off-label), resulting in long-term survival and cures [1].

pharmaceutical companies. This meant in practice that access to anticancer medicines was always significantly delayed for children [2] in contradiction with ethical principles and existing guidelines such as the International Conference on Harmonization guideline on the development of pediatric medicines (E11), which requires simultaneous submission for adults and children when the disease is serious or life threatening, when there are limited or no therapeutic alternatives [10].

In fact, behind the success lies another reality. If most of the success comes from effective treatments of acute pediatric leukemia and lymphoma, many other tumors – especially advanced stages and those of the CNS such as high-grade glioma – remain without effective therapeutic options, with short survival and devastating effects on the child and the family [3].

Regulatory initiatives in the USA, then in Europe, aim to ensure that medicines intended for adults are developed for children where there are unmet pediatric needs [10,103]. Unfortunately, to date in pediatric oncology these have not been so successful for several reasons. As part of the US Best Pharmaceutical for



Disclaimer

The views expressed in this article are those of the author and do not necessarily represent those of the European Medicines Agency.

Financial disclosure

The author has no financial or other interests in any of the products mentioned in this article.

be
fic

organization
ter or
ncies,

honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Log in via your institution

> [Access through your institution](#)

Log in to Taylor & Francis Online

> [Log in](#)

Restore content access

> [Restore content access for purchases made as guest](#)


Purchase options *

[Save for later](#)

PDF o

- 48 h
- Artic
- Artic


EUR 9

 Add to
cart

Iss

- Ar
- Artic

EUR 3

 Add to
cart

* Local tax



Related Research

People also read

Recommended articles

Cited by
11

Information for

- Authors
- R&D professionals
- Editors
- Librarians
- Societies

Opportunities

- Reprints and e-prints
- Advertising solutions
- Accelerated publication
- Corporate access solutions

Open access

- Overview
- Open journals
- Open Select
- Dove Medical Press
- F1000Research

Help and information

- Help and contact
- Newsroom
- All journals
- Books

Keep up to date

Register to receive updates
by email



Copyright

Accession

Registered
5 Howick Pl



Wiley & Francis Group
an informa business